Co-Authors
This is a "connection" page, showing publications co-authored by VARSHA V GANDHI and WILLIAM K PLUNKETT JR.
Connection Strength
6.574
-
Clofarabine and nelarabine: two new purine nucleoside analogs. Curr Opin Oncol. 2006 Nov; 18(6):584-90.
Score: 0.288
-
Pharmacokinetics and pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukemias. Clin Cancer Res. 2003 Dec 15; 9(17):6335-42.
Score: 0.236
-
Cellular and clinical pharmacology of fludarabine. Clin Pharmacokinet. 2002; 41(2):93-103.
Score: 0.206
-
Purine and pyrimidine nucleoside analogs. Cancer Chemother Biol Response Modif. 2001; 19:21-45.
Score: 0.192
-
Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy. Clin Cancer Res. 1997 Sep; 3(9):1539-45.
Score: 0.152
-
Incorporation of fludarabine and 1-beta-D-arabinofuranosylcytosine 5'-triphosphates by DNA polymerase alpha: affinity, interaction, and consequences. Clin Cancer Res. 1997 Aug; 3(8):1347-55.
Score: 0.152
-
Pharmacology of purine nucleoside analogues. Hematol Cell Ther. 1996 Dec; 38 Suppl 2:S67-74.
Score: 0.145
-
Gemcitabine: preclinical pharmacology and mechanisms of action. Semin Oncol. 1996 Oct; 23(5 Suppl 10):3-15.
Score: 0.143
-
Excision of 2',2'-difluorodeoxycytidine (gemcitabine) monophosphate residues from DNA. Cancer Res. 1996 Oct 01; 56(19):4453-9.
Score: 0.143
-
Intracellular pharmacodynamics in leukemia therapy. Rinsho Ketsueki. 1996 May; 37(5):369-79.
Score: 0.139
-
Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions. Blood. 1996 Jan 01; 87(1):256-64.
Score: 0.136
-
Preclinical characteristics of gemcitabine. Anticancer Drugs. 1995 Dec; 6 Suppl 6:7-13.
Score: 0.135
-
Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol. 1995 Aug; 22(4 Suppl 11):3-10.
Score: 0.132
-
Difluorodeoxyguanosine: cytotoxicity, metabolism, and actions on DNA synthesis in human leukemia cells. Semin Oncol. 1995 Aug; 22(4 Suppl 11):61-7.
Score: 0.132
-
Cytotoxicity, metabolism, and mechanisms of action of 2',2'-difluorodeoxyguanosine in Chinese hamster ovary cells. Cancer Res. 1995 Apr 01; 55(7):1517-24.
Score: 0.129
-
Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia. Clin Cancer Res. 1995 Feb; 1(2):169-78.
Score: 0.127
-
Effect of granulocyte-macrophage colony-stimulating factor on the metabolism of arabinosylcytosine triphosphate in blasts during therapy of patients with chronic myelogenous leukemia. Leukemia. 1994 Sep; 8(9):1463-8.
Score: 0.124
-
Omacetaxine: a protein translation inhibitor for treatment of chronic myelogenous leukemia. Clin Cancer Res. 2014 Apr 01; 20(7):1735-40.
Score: 0.119
-
Combination of fludarabine and arabinosylcytosine for treatment of chronic lymphocytic leukemia: clinical efficacy and modulation of arabinosylcytosine pharmacology. Cancer Chemother Pharmacol. 1994; 34(1):30-6.
Score: 0.118
-
Modulation of arabinosylcytosine metabolism during leukemia therapy. Adv Exp Med Biol. 1994; 370:119-24.
Score: 0.118
-
Evolution of the arabinosides and the pharmacology of fludarabine. Drugs. 1994; 47 Suppl 6:30-8.
Score: 0.118
-
Fludarabine inhibits DNA replication: a rationale for its use in the treatment of acute leukemias. Leuk Lymphoma. 1994; 14 Suppl 2:3-9.
Score: 0.118
-
Cellular pharmacology of fludarabine triphosphate in chronic lymphocytic leukemia cells during fludarabine therapy. Leuk Lymphoma. 1993 May; 10(1-2):49-56.
Score: 0.113
-
Cellular pharmacodynamics of anticancer drugs. Semin Oncol. 1993 Feb; 20(1):50-63.
Score: 0.111
-
Biochemical modulation of arabinosylcytosine for therapy of leukemias. Leuk Lymphoma. 1993; 10 Suppl:109-14.
Score: 0.110
-
Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J Clin Oncol. 1993 Jan; 11(1):116-24.
Score: 0.110
-
Fludarabine infusion potentiates arabinosylcytosine metabolism in lymphocytes of patients with chronic lymphocytic leukemia. Cancer Res. 1992 Feb 15; 52(4):897-903.
Score: 0.104
-
Cell cycle-specific metabolism of arabinosyl nucleosides in K562 human leukemia cells. Cancer Chemother Pharmacol. 1992; 31(1):11-7.
Score: 0.103
-
Metabolism and action of 2',2'-difluorodeoxycytidine: self-potentiation of cytotoxicity. Adv Exp Med Biol. 1991; 309A:125-30.
Score: 0.096
-
Metabolism and action of fludarabine phosphate. Semin Oncol. 1990 Oct; 17(5 Suppl 8):3-17.
Score: 0.094
-
Responses in mantle cell lymphoma cells to SNS-032 depend on the biological context of each cell line. Cancer Res. 2010 Aug 15; 70(16):6587-97.
Score: 0.093
-
Modulatory activity of 2',2'-difluorodeoxycytidine on the phosphorylation and cytotoxicity of arabinosyl nucleosides. Cancer Res. 1990 Jun 15; 50(12):3675-80.
Score: 0.092
-
Intracellular succinylation of 8-chloroadenosine and its effect on fumarate levels. J Biol Chem. 2010 Mar 12; 285(11):8022-30.
Score: 0.090
-
Modulation of arabinosylcytosine metabolism by arabinosyl-2-fluoroadenine in lymphocytes from patients with chronic lymphocytic leukemia: implications for combination therapy. Blood. 1989 Nov 01; 74(6):2070-5.
Score: 0.089
-
Interaction of arabinosyl nucleotides in K562 human leukemia cells. Biochem Pharmacol. 1989 Oct 15; 38(20):3551-8.
Score: 0.088
-
PROMISE: a tool to identify genomic features with a specific biologically interesting pattern of associations with multiple endpoint variables. Bioinformatics. 2009 Aug 15; 25(16):2013-9.
Score: 0.086
-
Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2009 May 07; 113(19):4637-45.
Score: 0.084
-
Polyadenylation inhibition by the triphosphates of deoxyadenosine analogues. Leuk Res. 2008 Oct; 32(10):1573-81.
Score: 0.080
-
Phase I trial of nelarabine in indolent leukemias. J Clin Oncol. 2008 Mar 01; 26(7):1098-105.
Score: 0.079
-
Modulation of arabinosylnucleoside metabolism by arabinosylnucleotides in human leukemia cells. Cancer Res. 1988 Jan 15; 48(2):329-34.
Score: 0.078
-
Separation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate and 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-triphosphate in human leukemia cells by high-performance liquid chromatography. J Chromatogr. 1987 Jan 23; 413:293-9.
Score: 0.073
-
A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia. Cancer Res. 2006 Nov 15; 66(22):10959-66.
Score: 0.072
-
Clinical and pharmacokinetic study of clofarabine in chronic lymphocytic leukemia: strategy for treatment. Clin Cancer Res. 2006 Jul 01; 12(13):4011-7.
Score: 0.070
-
Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial. Blood. 2006 Mar 15; 107(6):2517-24.
Score: 0.067
-
A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine). Blood. 2005 Dec 15; 106(13):4253-60.
Score: 0.066
-
Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death. Blood. 2005 Oct 01; 106(7):2513-9.
Score: 0.065
-
Clofarabine in adult acute leukemias: clinical success and pharmacokinetics. Nucleosides Nucleotides Nucleic Acids. 2004 Oct; 23(8-9):1417-23.
Score: 0.062
-
The expanding role of fludarabine in hematologic malignancies. Leuk Lymphoma. 1994; 14 Suppl 2:11-6.
Score: 0.059
-
Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia. Leuk Res. 2003 Dec; 27(12):1077-83.
Score: 0.059
-
New initiatives with fludarabine monophosphate in hematologic malignancies. Semin Oncol. 1993 Oct; 20(5 Suppl 7):13-20.
Score: 0.058
-
Prolonged infusion of gemcitabine: clinical and pharmacodynamic studies during a phase I trial in relapsed acute myelogenous leukemia. J Clin Oncol. 2002 Feb 01; 20(3):665-73.
Score: 0.052
-
New nucleoside analogues in clinical development. Cancer Chemother Biol Response Modif. 2002; 20:37-58.
Score: 0.051
-
Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J Clin Oncol. 2001 Aug 01; 19(15):3483-9.
Score: 0.050
-
Evaluation of the combination of nelarabine and fludarabine in leukemias: clinical response, pharmacokinetics, and pharmacodynamics in leukemia cells. J Clin Oncol. 2001 Apr 15; 19(8):2142-52.
Score: 0.049
-
High-performance liquid chromatography method for the determination and quantitation of arabinosylguanine triphosphate and fludarabine triphosphate in human cells. J Chromatogr B Biomed Sci Appl. 2000 Aug 18; 745(2):421-30.
Score: 0.047
-
Pharmacokinetics of nelarabine and 9-beta-D-arabinofuranosyl guanine in pediatric and adult patients during a phase I study of nelarabine for the treatment of refractory hematologic malignancies. J Clin Oncol. 2000 Mar; 18(5):995-1003.
Score: 0.045
-
Compound GW506U78 in refractory hematologic malignancies: relationship between cellular pharmacokinetics and clinical response. J Clin Oncol. 1998 Nov; 16(11):3607-15.
Score: 0.041
-
Cellular pharmacodynamics and plasma pharmacokinetics of parenterally infused hydroxyurea during a phase I clinical trial in chronic myelogenous leukemia. J Clin Oncol. 1998 Jul; 16(7):2321-31.
Score: 0.040
-
Influence of fludarabine on pharmacokinetics and pharmacodynamics of cytarabine: implications for a continuous infusion schedule. Clin Cancer Res. 1996 Apr; 2(4):653-8.
Score: 0.035
-
Phase I and extension study of clofarabine plus cyclophosphamide in patients with relapsed/refractory acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk. 2014 Jun; 14(3):231-8.
Score: 0.029
-
Fludarabine: pharmacokinetics, mechanisms of action, and rationales for combination therapies. Semin Oncol. 1993 Oct; 20(5 Suppl 7):2-12.
Score: 0.029
-
RRM1 and RRM2 pharmacogenetics: association with phenotypes in HapMap cell lines and acute myeloid leukemia patients. Pharmacogenomics. 2013 Sep; 14(12):1449-66.
Score: 0.029
-
Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2012 Aug; 12(4):244-51.
Score: 0.026
-
Inhibition of fludarabine metabolism by arabinosylcytosine during therapy. Cancer Chemother Pharmacol. 1992; 31(3):193-9.
Score: 0.026
-
Genetic variants in cytosolic 5'-nucleotidase II are associated with its expression and cytarabine sensitivity in HapMap cell lines and in patients with acute myeloid leukemia. J Pharmacol Exp Ther. 2011 Oct; 339(1):9-23.
Score: 0.025
-
Identification of predictive markers of cytarabine response in AML by integrative analysis of gene-expression profiles with multiple phenotypes. Pharmacogenomics. 2011 Mar; 12(3):327-39.
Score: 0.024
-
Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. J Clin Oncol. 2010 Jun 01; 28(16):2755-60.
Score: 0.023
-
Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance. Blood. 2009 Nov 12; 114(20):4441-50.
Score: 0.022
-
Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival. Cancer. 2008 Dec 01; 113(11):3181-5.
Score: 0.021
-
miRNAs and their potential for use against cancer and other diseases. Future Oncol. 2007 Oct; 3(5):521-37.
Score: 0.019
-
Pharmacogenetics of deoxycytidine kinase: identification and characterization of novel genetic variants. J Pharmacol Exp Ther. 2007 Dec; 323(3):935-45.
Score: 0.019
-
2-Chlorodeoxyadenosine and cytarabine combination therapy for idiopathic hypereosinophilic syndrome. Cancer. 2005 Aug 01; 104(3):541-6.
Score: 0.016
-
The role of clofarabine in hematologic and solid malignancies--development of a next-generation nucleoside analog. Cancer. 2005 May 15; 103(10):1985-95.
Score: 0.016
-
Population pharmacokinetics of clofarabine, a second-generation nucleoside analog, in pediatric patients with acute leukemia. J Clin Pharmacol. 2004 Nov; 44(11):1309-22.
Score: 0.016
-
Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood. 2005 Feb 01; 105(3):940-7.
Score: 0.016
-
Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood. 2004 Feb 01; 103(3):784-9.
Score: 0.015
-
Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood. 2003 Oct 01; 102(7):2379-86.
Score: 0.014
-
Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J Clin Oncol. 2003 Mar 15; 21(6):1167-73.
Score: 0.014
-
Interim comparison of a continuous infusion versus a short daily infusion of cytarabine given in combination with cladribine for pediatric acute myeloid leukemia. J Clin Oncol. 2002 Oct 15; 20(20):4217-24.
Score: 0.014
-
Action of (E)-2'-deoxy-2'-(fluoromethylene)cytidine on DNA metabolism: incorporation, excision, and cellular response. Mol Pharmacol. 2002 Jan; 61(1):222-9.
Score: 0.013
-
Sequential cis-platinum and fludarabine with or without arabinosyl cytosine in patients failing prior fludarabine therapy for chronic lymphocytic leukemia: a phase II study. Leuk Lymphoma. 1999 Dec; 36(1-2):57-65.
Score: 0.011
-
Complete hematologic and cytogenetic response to 2-amino-9-beta-D-arabinosyl-6-methoxy-9H-guanine in a patient with chronic myelogenous leukemia in T-cell blastic phase: a case report and review of the literature. Cancer. 1999 Jan 01; 85(1):58-64.
Score: 0.010
-
Clinical experience with fludarabine in hemato-oncology. Hematol Cell Ther. 1996 Dec; 38 Suppl 2:S83-91.
Score: 0.009
-
Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults. Leukemia. 1996 Oct; 10(10):1563-9.
Score: 0.009
-
The effect of 9-beta-D-arabinofuranosyl-2-fluoroadenine and 1-beta-D-arabinofuranosylcytosine on the cell cycle phase distribution, topoisomerase II level, mitoxantrone cytotoxicity, and DNA strand break production in K562 human leukemia cells. Cancer Chemother Pharmacol. 1996; 38(3):261-8.
Score: 0.008
-
Fludarabine--present status and future developments in chronic lymphocytic leukemia and lymphoma. Ann Oncol. 1994; 5 Suppl 2:79-83.
Score: 0.007
-
Fludarabine phosphate: a new active agent in hematologic malignancies. Semin Hematol. 1994 Jan; 31(1):28-39.
Score: 0.007
-
Fludarabine and cytosine arabinoside in the treatment of refractory or relapsed acute lymphocytic leukemia. Cancer. 1993 Oct 01; 72(7):2155-60.
Score: 0.007
-
Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia. Leuk Lymphoma. 1993 Mar; 9(4-5):343-50.
Score: 0.007
-
Comparison between the plasma and intracellular pharmacology of 1-beta-D-arabinofuranosylcytosine and 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate in patients with relapsed leukemia. Leukemia. 1987 Sep; 1(9):638-43.
Score: 0.005